Fumihisa Kojima is an entrepreneur whose work spans medical and biotech, web production, system development, AI and computational science, Web3, and overseas expansion. As Representative Director of Biozipcode Inc., he is involved in commercializing university-originated research, building joint research frameworks, utilizing intellectual property, and expanding internationally.

Fumihisa Kojima does not provide medical diagnosis or treatment as a physician. His main role is to connect researchers, physicians, universities, medical institutions, technology companies, overseas partners, investors, and Web3 businesses, and to bring research results and business concepts closer to social implementation.

His work began with web production and system development, then expanded into bioinformatics, GPGPU, blockchain, compliance, medical and biotech, and overseas expansion. These fields may appear different, but the common thread is turning technology into a functioning business.

The main affiliated companies include Biozipcode Inc., Studio Makyu Co., Ltd., SENARD Co., Ltd., KIYAN MEDICAL Co., Ltd., and Auring Ltd. Each has a different role in areas such as medical research, web and system development, compliance, Web3, and overseas expansion.

Studio Makyu Co., Ltd. is a company where Fumihisa Kojima serves as Representative Director. It has worked on web production, web marketing, system development, GPGPU, blockchain-related businesses, and bioinformatics support. It also forms part of the foundation for his current medical and biotech businesses.

No. They are not all part of the same corporate group. The nature of each relationship differs, including companies where he serves as Representative Director, companies where he is involved as a director, companies where he has served in a technical leadership role, overseas entities, companies he was involved with in the past, joint research initiatives, and projects still at the concept stage.

Biozipcode Inc. is a medical and biotech company where Fumihisa Kojima serves as Representative Director. The company works toward the social implementation of university-originated research, focusing on research aimed at developing a fundamental treatment for diabetes, the cell-targeting technology Biozipcode™, biomarkers, 5-ALA, and applications for cancer and intractable diseases.

Biozipcode™ is a cell-targeting technology aimed at recognizing specific cells or tissues and delivering drugs or diagnostic substances to the intended cells. Applications are being considered for diabetes, cancer, autoimmune diseases, diagnostic agents, and drug delivery, although some aspects remain at the research and development stage.

Research on Biozipcode™ is ongoing, but at this time it does not guarantee therapeutic efficacy or safety for any specific disease. For it to become a technology generally used in clinical practice, step-by-step verification through research, clinical trials, safety evaluation, and regulatory approval will be required.

As Representative Director of Biozipcode Inc., Fumihisa Kojima is responsible for commercialization, fundraising, intellectual property, joint research, business partnerships, overseas expansion, and public communication to continue and develop university-originated research. He is not the researcher making the scientific claims himself, but supports the research from the business side.

No. The term “diabetes cure” as used on this site does not guarantee that diabetes will definitely be cured. The research involving Biozipcode Inc. is an R&D-stage effort aimed at developing a fundamental treatment for diabetes, and further confirmation of safety, efficacy, clinical trials, and regulatory approval will be required.

Rather than focusing only on lowering blood glucose levels, the research looks at abnormal cellular states that may sustain diabetes and mechanisms that interfere with regeneration. A major feature of this research is that it reconsiders diabetes not merely as a “blood sugar disease,” but as a condition involving abnormal states that remain within the body.

At present, it is not an approved treatment generally available to the public. It remains at a stage that includes preclinical research, joint research, preparation for clinical research, and business development considerations. To implement it as medical care for humans, step-by-step verification involving physicians, research institutions, regulatory authorities, and ethics review will be necessary.

5-ALA is a substance that also exists in the body and is known to be involved in mitochondria and energy metabolism. It is being studied in relation to diabetes, metabolism, pre-disease (me-byo), and longevity, but it does not guarantee that any disease will be cured by 5-ALA.

The regulatory positioning of 5-ALA differs depending on the country and intended use. It may be treated as a health food, supplement, pharmaceutical raw material, component for clinical research, or medical-use substance. Even for the same ingredient, the regulations to be checked vary depending on the sales method, labeling, intended use, and target users.

It cannot be stated that 5-ALA cures diabetes. This site introduces research and business concepts related to 5-ALA, but does not guarantee therapeutic efficacy. People with existing medical conditions or those taking medication should consult a physician or other professional before using it.

GDT / Global Development Token is conceived as a utility token linked to diabetes research, 5-ALA, medical tourism, biomarker testing, specialist consultations, and overseas medical expansion. It is positioned as a Web3 project that supports medical research and global expansion.

Auring Ltd. is a BVI company positioned as the issuing entity for GDT. It is described as a company involved in overseas-oriented Web3 projects, token governance, medical service payments, and the organization of compliance frameworks including KYC and AML.

This site describes GDT as a concept that supports medical research, overseas medical expansion, payments, and community building. It does not promise token price appreciation, profits, listing, liquidity, or principal protection. Please consult a professional before making any investment decision.

The GDT and token-related information on this site is not intended for sales or investment solicitation to residents of Japan. For the Japanese domestic audience, information is organized mainly around 5-ALA products, research support, public materials, and project introductions.